A Case of Oral Semaglutide for Treatment of Hepatocyte Nuclear Factor 4A Maturity-Onset Diabetes of the Young

Background/ObjectiveMaturity-onset diabetes of the young (MODY) is a form of autosomal dominant monogenic diabetes.Sulfonylureas are the mainstay of therapy for HNF4A MODY.Here we present a patient with HNF4A MODY successfully treated with oral semaglutide.different mechanisms to bypass the malfunctioning pathway caused by the HNF4A MODY variant. ConclusionGLP-1RAs, including oral semaglutide, may be safe and efficacious treatments for patients with HNF4A MODY.